CyFlow™ CD14 FITC

CyFlow™ CD14 FITC
Laser: Blue
Target Species: Human, Non-Human Primates
Antigen: CD14
Field of Interest: Immunophenotyping
Clone: MEM-15
Regulatory Status: RUO
Alternative Name: LPS-R
Application: Flow cytometry
Format/Fluorochrome: FITC
Species of Origin: Mouse
Clonality: monoclonal
Emission Maximum: 518 nm
Excitation Maximum: 490 to 495 nm
Isotype: IgG1
Product number: CV308167

For Research Use Only

$235.00 USD*

Price excludes any applicable taxes plus shipping costs

HLDA Workshop HLDA III—WS Code M 252 HLDA IV—WS Code M 113 HLDA IV—WS Code NL 90 HLDA IV—WS... more
CyFlow™ CD14 FITC
HLDA WorkshopHLDA III—WS Code M 252 HLDA IV—WS Code M 113 HLDA IV—WS Code NL 90 HLDA IV—WS Code T 53 HLDA V—WS Code M MA086 HLDA VI—WS Code M MA94
Quantity100 tests
ImmunogenA crude mixture of human urinary proteins precipitated by ammonium sulphate from the urine of a patient suffering from proteinuria
SpecifityThe mouse monoclonal antibody MEM-15 recognizes CD14 antigen, a 53-55 kDa GPI (glycosylphosphatidylinositol)-linked membrane glycoprotein expressed on monocytes, macrophages and weakly on granulocytes; also expressed by most tissue macrophages. The antibody MEM-15 also reacts with soluble forms of CD14 found in serum and in the urine of some nephrotic patients.
Background InformationCD14 is a 55 kDa GPI-anchored glycoprotein, constitutively expressed on the surface of mature monocytes, macrophages, and neutrophils, where serves as a multifunctional lipopolysaccharide receptor; it is also released to the serum both as a secreted and enzymatically cleaved GPI-anchored form. CD14 binds lipopolysaccharide molecule in a reaction catalyzed by lipopolysaccharide-binding protein (LBP), an acute phase serum protein. The soluble sCD14 is able to discriminate slight structural differences between lipopolysaccharides and is important for neutralization of serum allochthonous lipopolysaccharides by reconstituted lipoprotein particles. CD14 affects allergic, inflammatory and infectious processes.
UsageThe reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 20·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (2 ml) is sufficient for 100 tests.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.1% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.

Specific References

| Bazil V, Horejsi V, Baudys M, Kristofova H, Strominger JL, Kostka W, Hilgert I: Biochemical characterization of a soluble form of the 53‑kDa monocyte surface antigen. Eur·J·Immunol. 1986·Dec; 16(12):1583‑9. <·PMID:·3493149·> | McMichael AJ, Beverley PCL, Cobbold S, et al (Eds): Leucocyte Typing III, White Cell Differentiation Antigens. Oxford·University·Press,·Oxford. 1987; 1‑1050. <·NLM·ID:·8913266·> | Knapp W, Dorken B, Gilks W, Rieber EP, Schmidt RE, Stein H, von dem Borne AEGK (Eds): Leucocyte Typing IV. Oxford·University·Press,·Oxford. 1989; 1‑1820. <·NLM·ID:·8914679·> | Doussis IA, Gatter KC, Mason DY: CD68 reactivity of non‑macrophage derived tumours in cytological specimens. J·Clin·Pathol. 1993·Apr; 46(4):334‑6. <·PMID:·7684403·> | Juan TS, Hailman E, Kelley MJ, Wright SD, Lichenstein HS: Identification of a domain in soluble CD14 essential for lipopolysaccharide (LPS) signaling but not LPS binding. J·Biol·Chem. 1995·Jul·21; 270(29):17237‑42. <·PMID:·7542233·> | Kishimoto T, Goyert S, Kikutani H, Mason D, Miyasaka M, Moretta L, Ohno T, Okumura K, Shaw S, Springer TA, Sugamura K, Sugawara H, von dem Borne AEGK, Zola H (Eds): Leucocyte Typing VI. Garland·Publishing·Inc,·New·York. 1997; 1‑1342. <·NLM·ID:·9712219·> | Schiff DE, Rae J, Martin TR, Davis BH, Curnutte JT: Increased phagocyte Fc gammaRI expression and improved Fc gamma‑receptor‑mediated phagocytosis after in vivo recombinant human interferon‑gamma treatment of normal human subjects. Blood. 1997·Oct·15; 90(8):3187‑94. <·PMID:·9376602·> | Funda DP, Tucková L, Farré MA, Iwase T, Moro I, Tlaskalová-Hogenová H: CD14 is expressed and released as soluble CD14 by human intestinal epithelial cells in vitro: lipopolysaccharide activation of epithelial cells revisited. Infect·Immun. 2001·Jun; 69(6):3772‑81. <·PMID:·11349042·> | Sing A, Rost D, Tvardovskaia N, Roggenkamp A, Wiedemann A, Kirschning CJ, Aepfelbacher M, Heesemann J: Yersinia V‑antigen exploits toll‑like receptor 2 and CD14 for interleukin 10‑mediated immunosuppression. J·Exp·Med. 2002·Oct·21; 196(8):1017‑24. <·PMID:·12391013·> | Fernández-Real JM, Broch M, Richart C, Vendrell J, López-Bermejo A, Ricart W: CD14 monocyte receptor, involved in the inflammatory cascade, and insulin sensitivity. J·Clin·Endocrinol·Metab. 2003·Apr; 88(4):1780‑4. <·PMID:·12679473·> | Lodrup Carlsen KC, Granum B: Soluble CD14: role in atopic disease and recurrent infections, including otitis media. Curr·Allergy·Asthma·Rep. 2007·Nov; 7(6):436‑43. <·PMID:·17986374·> | Asai Y, Makimura Y, Kawabata A, Ogawa T: Soluble CD14 discriminates slight structural differences between lipid as that lead to distinct host cell activation. J·Immunol. 2007·Dec·1; 179(11):7674‑83. <·PMID:·18025213·> | Kanderova V, Kuzilkova D, Stuchly J, Vaskova M, Brdicka T, Fiser K, Hrusak O, Lund‐Johansen F, Kalina T: High‐resolution antibody array analysis of childhood acute leukemia cells. Mol·Cell·Proteomics. 2016·Apr·1; 15(4):1246‐61. <·PMID:·26785729·>

Article successfully added.